The Effects of Gonadotropin Replacement Therapy in Patients With Hypogonadism

January 22, 2014 updated by: Aydogan Aydogdu, Gulhane School of Medicine
Effects of hCG replacement therapy on metabolic syndrome parameters in hypogonadotrophic hypogonadism.

Study Overview

Study Type

Observational

Enrollment (Actual)

16

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Ankara, Turkey, 06018
        • Gulhane School of Medicine Dep. of Endocrinology and Metabolism

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 45 years (ADULT, CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Sampling Method

Probability Sample

Study Population

Patients with Idiopathic Hypogonadotropic Hypogonadism

Description

Inclusion Criteria: Serum testosterone concentration < 300ng/dL Absence of a pituitary or hypothalamic mass lesions, Presence of gonadotropin response to GnRH, -

Exclusion Criteria: Previous androgen treatment, diabetes mellitus, arterial hypertension other hormone deficiencies

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
16 treatment naive Hypogonadotropic hypogonadism patients
Treatment naive 16 patients with idiopathic hypogonadotrophic hypogonadism
Other Names:
  • Pregnyl (Organon) ampule 1500 IU

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
HDL after hCG treatment
Time Frame: 2011-2013
2011-2013
2011-2013
LDL levels after hCG treatment
Time Frame: 2011-2013
2011-2013
total cholesterole levels after hCG treatment
Time Frame: 2011-2013
2011-2013

Secondary Outcome Measures

Outcome Measure
Time Frame
Body fat ratio after hCG treatment
Time Frame: 2011-2013
2011-2013
hsCRP levels after hCG treatment
Time Frame: 2011-2013
2011-2013

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Fahri Bayram, Proffesor, Erciyes University School of Medicine Depatment of Endocrinology and Metabolism Kayseri TURKEY

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2011

Primary Completion (ACTUAL)

August 1, 2013

Study Completion (ACTUAL)

August 1, 2013

Study Registration Dates

First Submitted

December 28, 2013

First Submitted That Met QC Criteria

January 22, 2014

First Posted (ESTIMATE)

January 23, 2014

Study Record Updates

Last Update Posted (ESTIMATE)

January 23, 2014

Last Update Submitted That Met QC Criteria

January 22, 2014

Last Verified

December 1, 2013

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Idiopathic Hypogonadotropic Hypogonadism

Clinical Trials on hCG 1500 IU three times a week

3
Subscribe